🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Check out our new paper in which we review what is currently known on how psychedelics acutely and post-acutely modulate fear conditioning, extinction learning, episodic memory, and semantic memory and how such effects may speak to treatment of PTSD. link.springer.com/article/10.100… 1/8

I had deactivated my account out of a sense of mental preservation, and was planning to log back in every 29 days to preserve my history and connections, but I apparently failed at that task. I'm now slowly rebuilding my twitter network.

New: We take a closer look at Gilgamesh's positive Phase 2a results of GM-2505 (aka bretisilocin, a serotonergic psychedelic) in major depressive disorder (MDD) & speak to company execs The results should provide a welcome catalyst for the field. psychedelicalpha.com/news/gilgamesh…

More details on those results from Gilgamesh's Ph 2a trial of GM-2505 in MDD. Impressive results from a 40-patient trial, which - given the candidate is a serotonergic psychedelic - could buoy the field. Read more, inc. interview with execs, in the article.

Check out our new review on the history and future of resting state fMRI 🧠 Bharat Biswal nature nature.com/articles/s4158…

Don’t miss this!

About to begin at Johns Hopkins University in Baltimore - happening right on the harbor: naturalphilosophyhopkins.org/natural-philos… David Chalmers Alison Gopnik Anil Seth Sean Carroll

I have trained many folks from mainland China. They were mostly great, enthusiastic, well trained, and knowledgeable. The vast majority would like to become US citizens and generally did not care for the various “political issues “ .

New in Nature Medicine: ReSPCT "An international Delphi consensus for reporting of setting in psychedelic clinical trials" by Chloé Pronovost-Morgan, Kyle Greenway, myself, and many ReSPCT Experts. "The ReSPCT guidelines and accompanying explanatory document provide a new standard for

As psychedelics gain traction as potential treatments for mental health disorders, an international study co-led by McGill University researchers stands to improve the rigour and reliability of clinical research. mcgill.ca/newsroom/chann…

At 2:22 the NIH Director asserts that they will continue to support health disparities research. Trust...but verify.

interesting analysis! Balázs Szigeti seems to be bracing for negative response, but why? non-inferiority in the clinical outcomes seems favorable overall, given prolonged side effects of chronic tAD treatment, vs focal and limited side effects of psilocybin

#CPDD25 is coming up quick! If you will be there Saturday afternoon - catch our workshop on Navigating a career in Addiction Science to hear from a variety of speakers from different career paths incl. Sheila Vakharia PhD MSW and Patricia Simon !

this is one wild ride, but there are a few exciting nuggets, including a fresh focus on replication as well as greater support for young investigators

The countdown to #CPDD25 begins! Be sure to attend our The College on Problems of Drug Dependence workshop "What's Your Best Pitch?" to learn how to pitch your science and vote for your favorite pitch Saturday June 14th from 1:00-2:30! Also check out i4sud.com for more ways to grow your science!

What does a 40% NIH budget cut mean for funding chances (now ~15%)? You might think “60% of the money left = 9% success” ❌ NOPE!!! 1-3% because 80% of the budget is for existing grants New science? Starved Ongoing grants? Slashed 😢 #FundingScienceSavesLives

If they can handcuff a U.S. Senator for asking a question, imagine what they will do to you.

This book is an amazing culmination of years of work and original thought and I can't really recommend more highly -- really pertinent for anyone interested in religion, psychedelics or mental health

Flow, psychedelics, and improvised mind states. The neuroscience behind what it means to lose yourself in music. 🎧 youtu.be/rqQfHm36KUc David S. Rosen, PhD | Johns Hopkins Psychedelic Research Center